Ser12

Site Information
RGAGQQQsQEMMEVD SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 460848
Associated spectra: 2 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 3 , 4 , 5 , 6 , 7 , 8 , 10 , 11 , 12 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 )
Disease tissue studied:	brain cancer ( 22 , 37 , 38 ) , glioblastoma ( 22 , 37 , 38 ) , glioma ( 22 , 37 , 38 ) , breast cancer ( 5 ) , breast ductal carcinoma ( 5 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 , 5 ) , cervical cancer ( 19 ) , cervical adenocarcinoma ( 19 ) , lung cancer ( 7 , 11 ) , non-small cell lung cancer ( 11 ) , non-small cell lung adenocarcinoma ( 7 ) , ovarian cancer ( 5 ) , pancreatic ductal adenocarcinoma ( 6 ) , melanoma skin cancer ( 3 )
Relevant cell line - cell type - tissue:	'pancreatic, ductal'-pancreas ( 6 ) , 293 (epithelial) [ADRB1 (human), no information, overexpresses human beta1-adrenergic (ß1AR- HEK293)] ( 21 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 17 ) , breast ( 1 , 5 ) , Calu 6 (pulmonary) ( 11 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 12 ) , Flp-In T-Rex-293 (epithelial) ( 12 ) , GM00130 (B lymphocyte) ( 18 ) , GM00200 (fibroblast) ( 23 , 24 ) , GM18366 (fibroblast) ( 25 , 26 ) , H2009 (pulmonary) ( 11 ) , H2077 (pulmonary) ( 11 ) , H2887 (pulmonary) ( 11 ) , H322M (pulmonary) ( 11 ) , HCC1359 (pulmonary) ( 11 ) , HCC4006 (pulmonary) ( 11 ) , HeLa (cervical) ( 4 , 14 , 16 ) , HeLa S3 (cervical) ( 19 ) , HUES-9 ('stem, embryonic') ( 15 ) , Jurkat (T lymphocyte) ( 8 ) , K562 (erythroid) ( 10 ) , lung ( 7 ) , M059J (glial) ( 34 , 38 ) , M059K (glial) ( 22 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 35 , 36 , 37 ) , NCI-H1648 (pulmonary) ( 11 ) , ovary ( 5 ) , WM115 (melanocyte) ( 20 ) , WM239A (melanocyte) ( 3 )

Upstream Regulation
Treatments:	ionizing_radiation ( 18 ) , ischemia ( 5 ) , MLN8054 ( 16 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
3	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
4	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
5	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
6	Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948 24670416 Curated Info
7	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
8	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
9	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
10	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
11	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
12	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
13	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
14	Zhou J (2011) CST Curation Set: 11708; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate (S/TQG) (P-S/T2-100) Rabbit mAb Cat#: 6966, PTMScan(R) Phospho-ATM/ATR Substrate Motif (S/TQG) Immunoaffinity Beads Cat#: 6969 Curated Info
15	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
16	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
17	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info
18	Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23 20164059 Curated Info
19	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
20	Old WM, et al. (2009) Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell 34, 115-31 19362540 Curated Info
21	Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50 18452278 Curated Info
22	Stokes M (2007) CST Curation Set: 2262; Year: 2007; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
23	Stokes M (2006) CST Curation Set: 1772; Year: 2006; Biosample/Treatment: cell line, GM00200/UV; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
24	Stokes M (2006) CST Curation Set: 1773; Year: 2006; Biosample/Treatment: cell line, GM00200/UV; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
25	Stokes M (2006) CST Curation Set: 1774; Year: 2006; Biosample/Treatment: cell line, GM18366/UV; Disease: Seckel syndrome; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
26	Stokes M (2006) CST Curation Set: 1775; Year: 2006; Biosample/Treatment: cell line, GM18366/UV; Disease: Seckel syndrome; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
27	Stokes M (2006) CST Curation Set: 1614; Year: 2006; Biosample/Treatment: cell line, M059K/untreated; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
28	Stokes M (2006) CST Curation Set: 1615; Year: 2006; Biosample/Treatment: cell line, M059K/untreated; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
29	Stokes M (2006) CST Curation Set: 1616; Year: 2006; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
30	Stokes M (2006) CST Curation Set: 1617; Year: 2006; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
31	Stokes M (2006) CST Curation Set: 1122; Year: 2006; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
32	Stokes M (2006) CST Curation Set: 1123; Year: 2006; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
33	Stokes M (2006) CST Curation Set: 1091; Year: 2006; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
34	Stokes M (2006) CST Curation Set: 1092; Year: 2006; Biosample/Treatment: cell line, M059J/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
35	Stokes M (2005) CST Curation Set: 1063; Year: 2005; Biosample1/Treatment/Isotope: cell line, M059K/none/L, Biosample2/Treatment/Isotope: cell line, M059K/UV/H; Disease: glioblastoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
36	Stokes M (2005) CST Curation Set: 994; Year: 2005; Biosample1/Treatment/Isotope: cell line, M059K/UV/L, Biosample2/Treatment/Isotope: cell line, M059K/UV/H; Disease: glioblastoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
37	Stokes M (2005) CST Curation Set: 909; Year: 2005; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
38	Stokes M (2005) CST Curation Set: 908; Year: 2005; Biosample/Treatment: cell line, M059J/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info